[go: up one dir, main page]

WO2008107377A3 - Combinations of markers for sepsis risk assessment - Google Patents

Combinations of markers for sepsis risk assessment Download PDF

Info

Publication number
WO2008107377A3
WO2008107377A3 PCT/EP2008/052474 EP2008052474W WO2008107377A3 WO 2008107377 A3 WO2008107377 A3 WO 2008107377A3 EP 2008052474 W EP2008052474 W EP 2008052474W WO 2008107377 A3 WO2008107377 A3 WO 2008107377A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
markers
combinations
risk assessment
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/052474
Other languages
French (fr)
Other versions
WO2008107377A2 (en
Inventor
Lieve Nuytinck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of WO2008107377A2 publication Critical patent/WO2008107377A2/en
Publication of WO2008107377A3 publication Critical patent/WO2008107377A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for determiningthe risk ofa subject to develop sepsis, severe sepsis or septic shockwhich comprise detecting the presence ofat least twonucleic acid variantsin a singlegeneor a combination of genes. The invention further provides tools and kits for performing these methods and the use of these methods in personalised therapy.
PCT/EP2008/052474 2007-03-02 2008-02-29 Combinations of markers for sepsis risk assessment Ceased WO2008107377A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103447.4 2007-03-02
EP07103447 2007-03-02

Publications (2)

Publication Number Publication Date
WO2008107377A2 WO2008107377A2 (en) 2008-09-12
WO2008107377A3 true WO2008107377A3 (en) 2008-11-27

Family

ID=38812018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/052474 Ceased WO2008107377A2 (en) 2007-03-02 2008-02-29 Combinations of markers for sepsis risk assessment

Country Status (1)

Country Link
WO (1) WO2008107377A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508618A1 (en) * 2011-04-04 2012-10-10 Innogenetics N.V. Methods and means for determining a functional polymorphism in ficolin-2 for predicting the outcome of kidney transplantation
WO2014190394A1 (en) * 2013-05-29 2014-12-04 Immunexpress Pty Ltd Microbial markers and uses therefor
CN107841551B (en) * 2017-09-29 2021-04-13 中国人民解放军第三军医大学第三附属医院 Application of single nucleotide polymorphisms in risk assessment of traumatic sepsis
CN115341024B (en) * 2022-03-24 2025-05-13 复旦大学附属华山医院 A method for detecting TLR10 rs11096957 genotype and its application in evaluating transplanted liver function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065626A2 (en) * 2003-01-17 2004-08-05 Rigshospitalet A method of sepsis prognosis
WO2006077248A1 (en) * 2005-01-21 2006-07-27 Innogenetics N.V. Nucleic acid variants in the ficolin genes associated with altered innate immunity
WO2007025989A2 (en) * 2005-09-02 2007-03-08 Innogenetics N.V. Nucleic acid variants in the toll like receptor genes associated with altered innate immunity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065626A2 (en) * 2003-01-17 2004-08-05 Rigshospitalet A method of sepsis prognosis
WO2006077248A1 (en) * 2005-01-21 2006-07-27 Innogenetics N.V. Nucleic acid variants in the ficolin genes associated with altered innate immunity
WO2007025989A2 (en) * 2005-09-02 2007-03-08 Innogenetics N.V. Nucleic acid variants in the toll like receptor genes associated with altered innate immunity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARCAROLI JOHN ET AL: "Genetic polymorphisms and sepsis", SHOCK, XX, XX, vol. 24, no. 4, October 2005 (2005-10-01), pages 300 - 312, XP009093769 *
BARBER ROBERT C ET AL: "Innate immunity SNPs are associated with risk for severe sepsis after burn injury.", CLINICAL MEDICINE & RESEARCH DEC 2006, vol. 4, no. 4, December 2006 (2006-12-01), pages 250 - 255, XP002491154, ISSN: 1539-4182 *
DATABASE SNP NCBI; 10 April 2003 (2003-04-10), IIPGA-WEISS-MARTINEZ: "SNP rs5743810", XP007905365, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. rs5743810 *
HEESEN MICHAEL ET AL: "The -260 C-->T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients.", INTENSIVE CARE MEDICINE AUG 2002, vol. 28, no. 8, August 2002 (2002-08-01), pages 1161 - 1163, XP002462757, ISSN: 0342-4642 *
LORENZ E ET AL: "a novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 68, no. 11, November 2000 (2000-11-01), pages 6398 - 6401, XP002377354, ISSN: 0019-9567 *
SUTHERLAND AINSLEY M ET AL: "Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults", CRITICAL CARE MEDICINE, WILLIAMS AND WILKINGS COMPANY, BALTIMORE, MA, US, vol. 33, no. 3, 2005, pages 638 - 644, XP009093803, ISSN: 0090-3493 *

Also Published As

Publication number Publication date
WO2008107377A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
WO2010129934A3 (en) Methods and compositions for diagnosis of thyroid conditions
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009102446A3 (en) Fish assay for eml4 and alk fusion in lung cancer
WO2007028161A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2008157264A3 (en) Combined methods for the detection of chromosomal aneuploidy
WO2007095186A8 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
MX338297B (en) Methods and compositions relating to fusions of alk for diagnosing and treating cancer.
EP2150625A4 (en) Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
WO2011039510A8 (en) Agents, uses and methods
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2009115615A3 (en) Detection and prognosis of cervical cancer
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2009037473A3 (en) Nucleobase characterisation
WO2010075360A3 (en) Methods for detection of sepsis
EP2262911A4 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
WO2008023840A3 (en) Prognostic markers and therapeutic targets for lung cancer
WO2009015359A3 (en) Highly visible chromosome-specific probes and related methods
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2007047408A3 (en) Promac signature application
WO2009014565A3 (en) Methods for diagnosing and treating astrocytomas
WO2011133947A3 (en) X-str multiplex system
WO2008107377A3 (en) Combinations of markers for sepsis risk assessment
WO2009103061A3 (en) Methods and compositions for identifying, diagnosing, and treating neuroblastoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08717255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08717255

Country of ref document: EP

Kind code of ref document: A2